Mayo Clinic Laboratories and KYAN Technologies enter a collaboration to expand patients’ access to cancer testing

ROCHESTER, Minn. and SINGAPORE, March 13, 2025 – Mayo Clinic Laboratories, a global leader in advanced laboratory testing, and KYAN Technologies, a leader in functional precision medicine for oncology, today announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States. This collaboration aims to support clinicians with additional testing insights for cancer treatment.

Optim.AI™ is a cutting-edge ex-vivo drug sensitivity platform that combines small data AI and biological experiments. The platform provides critical insights into effective therapies for cancer patients and delivers efficiencies for cancer drug development. Mayo Clinic Laboratories will provide testing for physicians and researchers to support clinical and research decision-making for better treatment options to as many patients as possible.

“At Mayo Clinic Laboratories, we are committed to offering a comprehensive portfolio of cancer testing,” said William Morice, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories. “This collaboration with KYAN Technologies provides another avenue for physicians to have access to the most robust and reliable diagnostic options available, empowering them to make informed decisions for better health outcomes and deliver customized treatment plans for their patients."

The KYAN test features drug plates that include multiple drugs, allowing for testing with minimal amounts of biological material compared to the standard process of choosing drugs and testing different combinations multiple times. This phenotypic response system efficiently solves large and complex search spaces to identify safe and effective drug-dose combination therapies, providing critical insights for drug development and therapy selection for patients.

Hugo Saavedra, CEO of KYAN Technologies, added, “We believe that this collaboration has the potential to advance cancer research and functional precision medicine by providing researchers and oncologists with additional tools to support cancer care.”

Mayo Clinic Laboratories is a for-profit, wholly owned subsidiary of Mayo Clinic. Mayo Clinic has an indirect financial interest in the technology referenced in this press release. Mayo Clinic will use any revenue received to support Mayo Clinic’s not-for-profit mission in patient care, education, and research.

About Mayo Clinic Laboratories 
Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for over 3,100 healthcare clients in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,200 tests and pathology services and performs more than 31 million tests annually.

About KYAN Technologies

KYAN Technologies is a biotechnology company on a mission to bridge the cancer care gap by advancing revolutionary technologies. Our Optim.AI™ technology platform has been clinically validated and offered as a test to clinicians and patients outside of the USA since 2023. Multiple clinical studies have highlighted the robustness and accuracy of Optim.AI™ in a range of cancers. Please visit our website to see our publications, presentations, and learn more. 

Contact:
Mayo Clinic Laboratories: newsbureau@mayo.edu

KYAN Technologies: info@kyantechnlogies.com